title: [Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants].
abstract: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. The use of bevacizumab has shown survival benefit in variety of cancers. However, a specific toxicity profile has been observed with bevacizumab such as hypertension, proteinuria, gastrointestinal perforation and arterial thrombosis. Non-small-cell lung cancer is often associated with thrombotic event therefore guidelines are expected to prescribe bevacizumab in this population. This article presents data from literature about the thrombotic risk and provides recommendations for the use of anticoagulant and antiaggregant treatments.
authors.affiliation: Centre René Gauducheau, Nantes, France. senellart@nantes.fnlclcc.fr
authors.forename: H
authors.initials: H
authors.lastname: Senellart
authors.forename: J
authors.initials: J
authors.lastname: Bennouna
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D012306:Risk; D054556:Venous Thromboembolism / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000068258:Bevacizumab